Can-Fite BioPharma Ltd. Operating Income Loss

• Can-Fite BioPharma Ltd. showed a decrease of -22.4% in Operating Income Loss from 2024 to 2025.
• This data is from Can-Fite BioPharma Ltd.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
• XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 8 years of available data (2018 to 2025), Can-Fite BioPharma Ltd.'s Operating Income Loss has declined by 83.8%.
• Historical annual values: Fiscal year 2025: -$9.95 million | Fiscal year 2024: -$8.13 million | Fiscal year 2023: -$8.20 million | Fiscal year 2022: -$10.10 million | Fiscal year 2021: -$12.84 million | Fiscal year 2020: -$14.14 million | Fiscal year 2019: -$12.01 million | Fiscal year 2018: -$5.41 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026